Partnerships Everest Medicines (Greater China rights, assigned from CORXEL Jun 2026); Lotus Pharmaceutical (Southeast Asia); Laboratoires Thea (Canada); Lunatus (Middle East distribution); Arrotex (Australia/New Zealand)
Indications
Presbyopia(Approved)
Status note FDA approved Jul 31, 2025 — first and only aceclidine-based eye drop for presbyopia; US NCE with 5-year exclusivity to Jul 2030 and patent protection to at least 2044. US commercial launch Aug 2025; retail pharmacies Nov 2025; telehealth channel Jul 2026. Company reports no ongoing clinical trials as of Jun 30, 2026.
Per-asset detail extracted from the 10-Q filed 2026-08-11. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
No specialist-fund holders in 13F data for this company.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.